NSE BSE
concord drugs limited stock

Concord Drugs Limited Share Price

- - (%)
Sector: -

538965

CONCORD

img img img img
No Data Available

Concord Drugs Limited : Share Price Update


As of the latest trading session, Concord Drugs Limited share price is currently at 38.02, which is up by 0.20 from its previous closing. Today, the stock has fluctuated between 37.40 and 40.00. Over the past year, Concord Drugs Limited has achieved a return of 25.03 %. In the last month alone, the return has been 3.24 %.

Concord Drugs Limited Performance

Day Range

Low37.40 High40.00
36.55

52 Week Range

Low 25.56 High 61.50
36.55

Open Price

39.00

Prev. Close

37.81

Volume (Shares)

3462.00

Total traded value

1.26

Upper Circuit

40.20

Lower Circuit

32.90

Note: The current prices & values are delayed, Login to your account for live updates.

Concord Drugs Limited Fundamentals


(Standalone)

Market Cap (Cr) 35.41
PE Ratio (TTM) 45.01
Book Value / Share 35.39
Beta 0.95
ROE 2.96%
EPS (TTM) 0.84
Dividend Yield 0.00%
Net Profit Qtr (Cr) -0.24

Concord Drugs Limited Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars DEC 2023 (Values in Cr)
Revenue 12.62
Operating Expense 12.87
Net Profit -0.24
Net Profit Margin (%) -1.90
Earnings Per Share (EPS) -0.24
EBITDA 0.55
Effective Tax Rate (%) 7.69
Particulars SEP 2023 (Values in Cr)
Revenue 7.38
Operating Expense 6.63
Net Profit 0.53
Net Profit Margin (%) 7.18
Earnings Per Share (EPS) 0.56
EBITDA 1.52
Effective Tax Rate (%) 31.57
Particulars JUN 2023 (Values in Cr)
Revenue 8.79
Operating Expense 8.16
Net Profit 0.49
Net Profit Margin (%) 5.57
Earnings Per Share (EPS) 0.52
EBITDA 1.40
Effective Tax Rate (%) 22.22
Particulars MAR 2023 (Values in Cr)
Revenue 11.54
Operating Expense 11.53
Net Profit 0.07
Net Profit Margin (%) 0.60
Earnings Per Share (EPS) 0.07
EBITDA 0.75
Effective Tax Rate (%) -250.00
Particulars DEC 2022 (Values in Cr)
Revenue 13.53
Operating Expense 12.91
Net Profit 0.45
Net Profit Margin (%) 3.32
Earnings Per Share (EPS) 0.52
EBITDA 1.45
Effective Tax Rate (%) 25.80
Particulars MAR 2023 (Values in Cr)
Revenue 51.31
Operating Expense 50.19
Net Profit 0.89
Net Profit Margin (%) 1.73
Earnings Per Share (EPS) 0.96
EBITDA 4.35
Effective Tax Rate (%) 20.35
Particulars MAR 2022 (Values in Cr)
Revenue 58.96
Operating Expense 56.81
Net Profit 1.59
Net Profit Margin (%) 2.69
Earnings Per Share (EPS) 1.82
EBITDA 5.68
Effective Tax Rate (%) 28.88
Particulars MAR 2021 (Values in Cr)
Revenue 51.36
Operating Expense 50.92
Net Profit 3.28
Net Profit Margin (%) 6.38
Earnings Per Share (EPS) 3.75
EBITDA 7.08
Effective Tax Rate (%) 23.54
Particulars MAR 2020 (Values in Cr)
Revenue 51.34
Operating Expense 51.00
Net Profit 0.33
Net Profit Margin (%) 0.64
Earnings Per Share (EPS) 0.38
EBITDA 3.46
Effective Tax Rate (%) 28.26
Particulars MAR 2019 (Values in Cr)
Revenue 48.08
Operating Expense 47.72
Net Profit 0.41
Net Profit Margin (%) 0.85
Earnings Per Share (EPS) 0.52
EBITDA 3.74
Effective Tax Rate (%) 6.81
Particulars MAR 2023 (Values in Cr)
Book Value / Share 33.43
ROE % 3.30
ROCE % 6.04
Total Debt to Total Equity 0.56
EBITDA Margin 8.79
Particulars MAR 2022 (Values in Cr)
Book Value / Share 32.44
ROE % 5.61
ROCE % 8.36
Total Debt to Total Equity 0.58
EBITDA Margin 9.65
Particulars MAR 2023 (Values in Cr)
Book Value / Share 33.43
ROE % 2.96
ROCE % 5.67
Total Debt to Total Equity 0.53
EBITDA Margin 8.48
Particulars MAR 2022 (Values in Cr)
Book Value / Share 32.44
ROE % 5.77
ROCE % 8.80
Total Debt to Total Equity 0.53
EBITDA Margin 9.65
Particulars MAR 2021 (Values in Cr)
Book Value / Share 30.61
ROE % 1.59
ROCE % 5.01
Total Debt to Total Equity 0.45
EBITDA Margin 6.46
Particulars MAR 2020 (Values in Cr)
Book Value / Share 26.86
ROE % 1.42
ROCE % 5.61
Total Debt to Total Equity 0.42
EBITDA Margin 6.74
Particulars MAR 2019 (Values in Cr)
Book Value / Share 29.45
ROE % 1.93
ROCE % 5.69
Total Debt to Total Equity 0.55
EBITDA Margin 7.78
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.09
Total Assets 58.23
Total Liabilities 58.23
Total Equity 31.70
Share Outstanding 9315470
Price to Book Ratio 0.82
Return on Assets (%) 1.69
Return on Capital (%) 2.06
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.06
Total Assets 56.44
Total Liabilities 56.44
Total Equity 28.36
Share Outstanding 8743750
Price to Book Ratio 0.89
Return on Assets (%) 2.82
Return on Capital (%) 3.62
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.09
Total Assets 56.63
Total Liabilities 56.63
Total Equity 31.70
Share Outstanding 9315470
Price to Book Ratio 0.82
Return on Assets (%) 1.57
Return on Capital (%) 1.92
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.06
Total Assets 56.44
Total Liabilities 56.44
Total Equity 28.36
Share Outstanding 8743750
Price to Book Ratio 0.89
Return on Assets (%) 2.82
Return on Capital (%) 3.62
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.05
Total Assets 49.88
Total Liabilities 49.88
Total Equity 26.76
Share Outstanding 8743750
Price to Book Ratio 0.95
Return on Assets (%) 6.57
Return on Capital (%) 8.26
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 0.03
Total Assets 58.01
Total Liabilities 58.01
Total Equity 23.48
Share Outstanding 8743750
Price to Book Ratio 0.49
Return on Assets (%) 0.56
Return on Capital (%) 0.99
Particulars MAR 2019 (Values in Cr)
Cash & Short Term Investments 0.18
Total Assets 82.76
Total Liabilities 82.76
Total Equity 23.15
Share Outstanding 7861750
Price to Book Ratio 0.71
Return on Assets (%) 0.49
Return on Capital (%) 1.23
Particulars MAR 2023 (Values in Cr)
Net Income 1.24
Cash from Operations 2.04
Cash from Investing -2.26
Cash from Financing 0.62
Net change in Cash 0.02
Free Cash Flow 2.89
Particulars MAR 2022 (Values in Cr)
Net Income 2.24
Cash from Operations 1.44
Cash from Investing -2.44
Cash from Financing 1.67
Net change in Cash 0.00
Free Cash Flow 3.90
Particulars MAR 2023 (Values in Cr)
Net Income 1.12
Cash from Operations 2.59
Cash from Investing -2.26
Cash from Financing 0.05
Net change in Cash 0.03
Free Cash Flow 3.44
Particulars MAR 2022 (Values in Cr)
Net Income 2.24
Cash from Operations 1.44
Cash from Investing -2.44
Cash from Financing 1.67
Net change in Cash 0.00
Free Cash Flow 3.90
Particulars MAR 2021 (Values in Cr)
Net Income 4.29
Cash from Operations 2.08
Cash from Investing -3.66
Cash from Financing 2.07
Net change in Cash 0.02
Free Cash Flow 5.76
Particulars MAR 2020 (Values in Cr)
Net Income 0.45
Cash from Operations 2.60
Cash from Investing -0.84
Cash from Financing -1.79
Net change in Cash -0.14
Free Cash Flow 3.45
Particulars MAR 2019 (Values in Cr)
Net Income 0.43
Cash from Operations 1.31
Cash from Investing -0.34
Cash from Financing -0.73
Net change in Cash 0.11
Free Cash Flow 1.65
Company Name Price P/E P/B Market Cap 52 Week Low/High
Concord Drugs Limited 37.81 38.98 1.06 37.81 25.56 / 61.50
BLISS GVS PHARMA LTD 109.15 11.93 1.18 1142.70 71.00 / 148.95
CIPLA LTD 1420.05 26.93 4.29 114654.12 911.80 / 1519.00
FERMENTA BIOTECH LIMITED 160.95 0.00 1.65 473.69 132.30 / 214.00
GLAXOSMITHKLINE PHARMA LT 2023.85 53.46 22.26 34285.24 1265.00 / 2649.95
Company Name Price P/E P/B Market Cap 52 Week Low/High
Concord Drugs Limited 37.81 45.01 1.06 37.81 25.56 / 61.50
AMRUTAJAN HEALTH LTD 749.30 49.23 8.26 2166.27 556.05 / 802.60
ASTRAZENECA PHARMA IND LT 5639.25 88.39 21.52 14098.13 3131.10 / 7208.00
BLISS GVS PHARMA LTD 109.15 15.08 1.15 1142.70 71.00 / 148.95
ABBOTT INDIA LIMITED 26545.40 46.96 15.25 56408.98 20594.25 / 29628.15

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 36.70
  • 26 Days 36.80
  • 10 Days 36.60
  • 50 Days 37.20
  • 12 Days 36.70
  • 100 Days 39.40
  • 20 Days 36.60
  • 200 Days 28.40
36.84
PIVOT
First Resistance 37.68
Second Resistance 38.81
Third Resistance 39.65
First Support 35.71
Second Support 34.87
Third Support 33.74
RSI 56.23
MACD -0.18
Commodity Channel Index (CCI) 95.64
ADX 25.84
Williams % R -35.13

Over 1 Month

down

3.24

Over 3 Months

down

-6.48

Over 6 Months

down

12.12

Over 1 Year

down

25.03

Over 3 Years

down

2.41

Over 5 Years

down

10.40

Concord Drugs Limited Future

Future: Price

25 May
0 100 200 300 400 500 600

Discount/Premium

25 May
0 1 2 3 4 5 6 7

Active Calls

25 May
0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul
0 500 1000 1500 2000 2500

Concord Drugs Limited Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Holding

Others
0.0
Promoter Holdings
0.0
FII
0.0
DII
0.0
Promoter Shares(Pledge Percentage)
0.0
Name Category Shares Shares%
Nagi Reddy Seelam Shareholding of Promoter and Promoter Group 2912524.0 29.13
Manoj Kumar Reddy Seelam Shareholding of Promoter and Promoter Group 1628125.0 16.28
Seelam Koni Reddy Shareholding of Promoter and Promoter Group 1000000.0 10.0
Rajender Kumar Agarwal Public Shareholding 168633.0 1.69
Sushil Kumar Agarwal Public Shareholding 130400.0 1.3
Mohan Thodupunuri Public Shareholding 130140.0 1.3
S N Thulasi Devi Public Shareholding 121200.0 1.21
K Ramesh Reddy Public Shareholding 104600.0 1.05
Mohan Thodupunuri Public Shareholding 100006.0 1.0
Ekta Vijaywargi Public Shareholding 100000.0 1.0
Rakesh K Public Shareholding 100000.0 1.0
Sannuthi Lokesh Public Shareholding 100000.0 1.0

Concord Drugs Limited

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
Ex-Date Ex-Bonus Ratio
Ex-Date Old FV NEW FV Record Date

Learn More About Stocks

About Concord Drugs Limited

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by Concord Drugs Limited

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 5x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Frequently Asked Questions

What is the Share Price of Concord Drugs Ltd?

Answer Field

The share price of Concord Drugs Ltd for NSE is ₹ 0.00 and for BSE is ₹ 38.02.

What is the Market Cap of Concord Drugs Ltd?

Answer Field

The market cap of Concord Drugs Ltd for NSE is ₹ 0.0 Cr. and for BSE is ₹ 35.41 Cr. as of now.

What is the 52 Week High and Low of Concord Drugs Ltd?

Answer Field

The 52 Week High and Low of Concord Drugs Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 61.50 and ₹ 25.56.

How to Buy Concord Drugs Ltd share?

Answer Field

You can trade in Concord Drugs Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Concord Drugs Ltd?

Answer Field

The 1 year returns on the stock has been 25.03%.

No results found

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

7 Lac+ Users

icon-with-text

4.3 App Rating

icon-with-text

4 Languages

icon-with-text

₹ 3800 Cr MTF Book

icon-with-text
loader